I

Ionis Pharmaceuticals
D

IONS

32.780
USD
1.10
(3.47%)
مغلق
حجم التداول
66,728
الربح لكل سهم
-4
العائد الربحي
-
P/E
-11
حجم السوق
5,217,235,265
أصول ذات صلة
ALNY
ALNY
3.98
(1.56%)
259.33 USD
A
AXDX
-0.03500
(-6.14%)
0.53500 USD
C
CRSP
0.520
(1.38%)
38.220 USD
E
EDIT
0.01500
(0.93%)
1.63000 USD
GILD
GILD
0.420
(0.41%)
103.660 USD
MRNA
MRNA
0.600
(2.22%)
27.590 USD
REGN
REGN
15.98
(2.71%)
606.12 USD
S
SGMO
-0.01210
(-1.63%)
0.72800 USD
S
SRPT
0.740
(1.18%)
63.550 USD
VRTX
VRTX
2.22
(0.45%)
500.92 USD
المزيد
الأخبار المقالات

العنوان: Ionis Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.